» Articles » PMID: 10948118

Toxoids of Streptococcal Pyrogenic Exotoxin A Are Protective in Rabbit Models of Streptococcal Toxic Shock Syndrome

Overview
Journal Infect Immun
Date 2000 Aug 19
PMID 10948118
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Streptococcal pyrogenic exotoxins (SPEs) are superantigens that have been implicated in causing streptococcal toxic shock syndrome (STSS). Most notably, SPE serotype A is made by nearly all M-protein serotype 1 and 3 streptococci, the M types most associated with the illness (these strains contain one or more other SPEs, and those proteins are likely also to contribute to disease). We have prepared double-, triple-, and hexa-amino-acid mutants of SPE A by PCR and other mutagenesis procedures. The sites chosen for mutation were solvent-exposed residues thought to be important for T-cell receptor (TCR) or major histocompatibility complex (MHC) class II interaction. These mutants were nonsuperantigenic for human peripheral blood mononuclear cells and rabbit and mouse splenocytes and were nonlethal in two rabbit models of STSS. In addition, these mutants stimulated protective antibody responses. Interestingly, mutants that altered toxin binding to MHC class II were more immunogenic than mutants altering TCR binding. Collectively, these studies indicate that multiple-site mutants of SPE A are toxoids that may have use in protecting against the toxin's effects in STSS.

Citing Articles

Novel insights into the immune response to bacterial T cell superantigens.

Tuffs S, Dufresne K, Rishi A, Walton N, McCormick J Nat Rev Immunol. 2024; 24(6):417-434.

PMID: 38225276 DOI: 10.1038/s41577-023-00979-2.


Staphylococcal Enterotoxin B and C Mutants and Vaccine Toxoids.

Schlievert P Microbiol Spectr. 2023; :e0444622.

PMID: 36815779 PMC: 10101070. DOI: 10.1128/spectrum.04446-22.


Streptococcal superantigens and the return of scarlet fever.

Hurst J, Brouwer S, Walker M, McCormick J PLoS Pathog. 2021; 17(12):e1010097.

PMID: 34969060 PMC: 8717983. DOI: 10.1371/journal.ppat.1010097.


A brief review on Group A Streptococcus pathogenesis and vaccine development.

Ajay Castro S, Dorfmueller H R Soc Open Sci. 2021; 8(3):201991.

PMID: 33959354 PMC: 8074923. DOI: 10.1098/rsos.201991.


SpeS: A Novel Superantigen and Its Potential as a Vaccine Adjuvant against Strangles.

Dominguez-Medina C, Rash N, Robillard S, Robinson C, Efstratiou A, Broughton K Int J Mol Sci. 2020; 21(12).

PMID: 32586031 PMC: 7352279. DOI: 10.3390/ijms21124467.


References
1.
Mascini E, Jansze M, Schellekens J, Musser J, Faber J, Schouls L . Invasive group A streptococcal disease in the Netherlands: evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis. 2000; 181(2):631-8. DOI: 10.1086/315222. View

2.
Yu C, Ferretti J . Molecular epidemiologic analysis of the type A streptococcal exotoxin (erythrogenic toxin) gene (speA) in clinical Streptococcus pyogenes strains. Infect Immun. 1989; 57(12):3715-9. PMC: 259895. DOI: 10.1128/iai.57.12.3715-3719.1989. View

3.
NAUCIEL C, Blass J, MANGALO R, Raynaud M . Evidence for two molecular forms of streptococcal erythrogenic toxin. Conversion to a single form by 2-mercaptoethanol. Eur J Biochem. 1969; 11(1):160-4. DOI: 10.1111/j.1432-1033.1969.tb00754.x. View

4.
Kim Y, Watson D . A purified group A streptococcal pyrogenic exotoxin. Physiochemical and biological properties including the enhancement of susceptibility to endotoxin lethal shock. J Exp Med. 1970; 131(3):611-22. PMC: 2138823. DOI: 10.1084/jem.131.3.611. View

5.
Barsumian E, Schlievert P, Watson D . Nonspecific and specific immunological mitogenicity by group A streptococcal pyrogenic exotoxins. Infect Immun. 1978; 22(3):681-8. PMC: 422214. DOI: 10.1128/iai.22.3.681-688.1978. View